Luminex Corp. (NASDAQ:LMNX) saw unusually-high trading volume on Wednesday . Approximately 444,108 shares changed hands during trading, an increase of 68% from the previous session’s volume of 263,706 shares.The stock last traded at $22.05 and had previously closed at $22.27.

LMNX has been the topic of a number of research analyst reports. Zacks Investment Research downgraded Luminex Corp. from a “buy” rating to a “hold” rating in a report on Thursday, April 14th. Leerink Swann reiterated a “hold” rating and set a $22.00 target price on shares of Luminex Corp. in a report on Tuesday, May 3rd. Finally, Piper Jaffray Cos. reiterated a “hold” rating and set a $20.00 target price (up previously from $19.00) on shares of Luminex Corp. in a report on Tuesday, May 3rd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $20.83.

The firm has a 50 day moving average of $20.43 and a 200-day moving average of $19.71. The company has a market cap of $955.65 million and a P/E ratio of 24.78.

Luminex Corp. (NASDAQ:LMNX) last announced its quarterly earnings data on Monday, May 2nd. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.15. During the same period last year, the firm earned $0.23 earnings per share. The company had revenue of $63 million for the quarter, compared to analysts’ expectations of $60.98 million. Luminex Corp.’s quarterly revenue was up 9.2% compared to the same quarter last year. Analysts forecast that Luminex Corp. will post $0.67 earnings per share for the current fiscal year.

Other large investors recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its stake in shares of Luminex Corp. by 18.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,054,266 shares of the company’s stock worth $22,551,000 after buying an additional 162,753 shares during the period. Tamarack Advisers LP bought a new stake in shares of Luminex Corp. during the fourth quarter worth $19,786,000. Oxford Asset Management raised its stake in shares of Luminex Corp. by 25.3% in the fourth quarter. Oxford Asset Management now owns 92,041 shares of the company’s stock worth $1,984,000 after buying an additional 18,562 shares during the period. Rhumbline Advisers raised its stake in shares of Luminex Corp. by 4.6% in the fourth quarter. Rhumbline Advisers now owns 69,917 shares of the company’s stock worth $1,496,000 after buying an additional 3,100 shares during the period. Finally, American Century Companies Inc. raised its stake in shares of Luminex Corp. by 0.4% in the fourth quarter. American Century Companies Inc. now owns 160,075 shares of the company’s stock worth $3,424,000 after buying an additional 705 shares during the period.

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.